The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections
Open accessAbstract
Herpesviruses infect the majority of the human population and can cause significant morbidity and mortality. Herpes simplex virus (HSV) type 1 causes cold sores and herpes simplex keratitis, whereas HSV-2 is responsible for genital herpes. Human cytomegalovirus (HCMV) is the most common viral cause of congenital defects and is responsible for serious disease in immuno-compromised individuals. Epstein-Barr virus (EBV) is associated with infectious mononucleosis and a broad range of malignancies, including Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, and post-transplant lymphomas. Herpesviruses persist in their host for life by establishing a latent infection that is interrupted by periodic reactivation events during which replication occurs. Current antiviral drug treatments target the clinical manifestations of this productive stage, but they are ineffective at eliminating these viruses from the infected host. Here, we set out to combat both productive and latent herpesvirus infections by exploiting the CRISPR/Cas9 system to target viral genetic elements important for virus fitness. We show effective abrogation of HCMV and HSV-1 replication by targeting gRNAs to essential viral genes. Simultaneous targeting of HSV-1 with multiple gRNAs completely abolished the production of infectious particles from human cells. Using the same approach, EBV can be almost completely cleared from latently infected EBV-transformed human tumor cells. Our studies indicate that the CRISPR/Cas9 system can be effectively targeted to herpesvirus genomes as a potent prophylactic and therapeutic anti-viral strategy that may be used to impair viral replication and clear latent virus infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“Thus, instead of using single gRNAs to target herpesviruses, simultaneous administering of multiple CRISPR gRNAs will further reduce the likelihood of generating escape mutants as the viral genome will not only be mutagenized at multiple essential sites, but will also become fragmented The potential of the CRISPR/Cas9…”
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,465
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“Another study describes the use of tru-gRNAs, where shortened gRNAs retain their potent ontarget activity, but show much reduced off-target editing [71].”
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation
Doench, J. G., Hartenian, E., Graham, D. B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B. L., Xavier, R. J., & Root, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.3026 · Cited by 1,617
Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells
Yates, J. L., Warren, N., & Sugden, B. (1985) · Nature · doi:10.1038/313812a0 · Cited by 1,292
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197
Using Tablet for visual exploration of second-generation sequencing data
Milne, I., Stephen, G., Bayer, M., Cock, P. J. A., Pritchard, L., Cardle, L., Shaw, P. D., & Marshall, D. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs012 · Cited by 973
Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells
Wu, X., Scott, D. A., Kriz, A. J., Chiu, A. C., Hsu, P. D., Dadon, D. B., Cheng, A. W., Trevino, A. E., Konermann, S., Chen, S., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2889 · Cited by 944
Riballo, E., Kühne, M., Rief, N., Doherty, A., Smith, G. C. M., Recio, M.-J., Reis, C., Dahm, K., Fricke, A., Krempler, A., et al. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.029 · Cited by 837
Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease
Kuscu, C., Arslan, S., Singh, R., Thorpe, J., & Adli, M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2916 · Cited by 777
Functional profiling of a human cytomegalovirus genome
Dunn, W., Chou, C., Li, H., Hai, R., Patterson, D., Stolc, V., Zhu, H., & Liu, F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2334032100 · Cited by 645
Heritable gene targeting in the mouse and rat using a CRISPR-Cas system
Li, D., Qiu, Z., Shao, Y., Chen, Y., Guan, Y., Liu, M., Li, Y., Gao, N., Wang, L., Lu, X., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2661 · Cited by 643
Cre-lox-regulated conditional RNA interference from transgenes
Ventura, A., Meissner, A., Dillon, C. P., McManus, M., Sharp, P. A., Van Parijs, L., Jaenisch, R., & Jacks, T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403954101 · Cited by 625
Evolutionary analysis of the dynamics of viral infectious disease
Pybus, O. G., & Rambaut, A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2583 · Cited by 620
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565 · cited 2×
“The CRISPR/Cas9 system has also been engineered to selectively modify dsDNA viruses [23 – 30], positive-sense single stranded RNA viruses, such as Hepatitis C [31] and integrated HIV proviral DNA in human cells [32 – 36].”
Topics in herpesvirus genomics and evolution
McGeoch, D. J., Rixon, F. J., & Davison, A. J. (2006) · Virus Research · doi:10.1016/j.virusres.2006.01.002 · Cited by 544
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405186111 · Cited by 527
Rawlins, D. R., Milman, G., Hayward, S. D., & Hayward, G. S. (1985) · Cell · doi:10.1016/0092-8674(85)90282-x · Cited by 506
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475 · cited 1×
“Researchers are now able to generate full knockouts for any gene in any cell-type [17, 18], induce specific editing/mutagenesis of loci [15, 17, 19], edit multiple alleles simultaneously [20, 21], in addition to many other applications [12, 15, 22].”
Sugden, B., Marsh, K., & Yates, J. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.2.410 · Cited by 440
Reisman, D., Yates, J., & Sugden, B. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.8.1822 · Cited by 436
Functional map of human cytomegalovirus AD169 defined by global mutational analysis
Yu, D., Silva, M. C., & Shenk, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635160100 · Cited by 409
Expanding the Biologist’s Toolkit with CRISPR-Cas9
Sternberg, S. H., & Doudna, J. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.032 · Cited by 404
Reisman, D., & Sugden, B. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.11.3838 · Cited by 366
Efficient Intracellular Delivery of Native Proteins
D’Astolfo, D. S., Pagliero, R. J., Pras, A., Karthaus, W. R., Clevers, H., Prasad, V., Lebbink, R. J., Rehmann, H., & Geijsen, N. (2015) · Cell · doi:10.1016/j.cell.2015.03.028 · Cited by 338
Self-citationUse of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells
Liao, H.-K., Gu, Y., Diaz, A., Marlett, J., Takahashi, Y., Li, M., Suzuki, K., Xu, R., Hishida, T., Chang, C.-J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7413 · Cited by 336
Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing
Kaminski, R., Chen, Y., Fischer, T., Tedaldi, E., Napoli, A., Zhang, Y., Karn, J., Hu, W., & Khalili, K. (2016) · Scientific Reports · doi:10.1038/srep22555 · Cited by 315
Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in Brain
Bartlett, J. S., Samulski, R. J., & McCown, T. J. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.8-1181 · Cited by 301
The molecular basis of herpes simplex virus latency
Nicoll, M. P., Proença, J. T., & Efstathiou, S. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00320.x · Cited by 286
Molesworth, S. J., Lake, C. M., Borza, C. M., Turk, S. M., & Hutt-Fletcher, L. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.14.6324-6332.2000 · Cited by 281
Kennedy, E. M., Kornepati, A. V. R., Goldstein, M., Bogerd, H. P., Poling, B. C., Whisnant, A. W., Kastan, M. B., & Cullen, B. R. (2014) · Journal of Virology · doi:10.1128/jvi.01879-14 · Cited by 262
Cas9-mediated targeting of viral RNA in eukaryotic cells
Price, A. A., Sampson, T. R., Ratner, H. K., Grakoui, A., & Weiss, D. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422340112 · Cited by 250
RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection
Wang, J., & Quake, S. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410785111 · Cited by 220
Zhen, S., Hua, L., Takahashi, Y., Narita, S., Liu, Y.-H., & Li, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.014 · Cited by 219
Kennedy, E. M., Bassit, L. C., Mueller, H., Kornepati, A. V. R., Bogerd, H. P., Nie, T., Chatterjee, P., Javanbakht, H., Schinazi, R. F., & Cullen, B. R. (2015) · Virology · doi:10.1016/j.virol.2014.12.001 · Cited by 209
Reisman, D., Yates, J., & Sugden, B. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.8.1822-1832.1985 · Cited by 186
Sakaoka, H., Kurita, K., Iida, Y., Takada, S., Umene, K., Kim, Y. T., Ren, C. S., & Nahmias, A. J. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-3-513 · Cited by 173
CRISPR/Cas9-mediated genome editing of Epstein–Barr virus in human cells
Yuen, K.-S., Chan, C.-P., Wong, N.-H. M., Ho, C.-H., Ho, T.-H., Lei, T., Deng, W., Tsao, S. W., Chen, H., Kok, K.-H., et al. (2015) · Journal of General Virology · doi:10.1099/jgv.0.000012 · Cited by 168
Human Cytomegalovirus UL38 Protein Blocks Apoptosis
Terhune, S., Torigoi, E., Moorman, N., Silva, M., Qian, Z., Shenk, T., & Yu, D. (2007) · Journal of Virology · doi:10.1128/jvi.02124-06 · Cited by 160
Zhang, Y., Yin, C., Zhang, T., Li, F., Yang, W., Kaminski, R., Fagan, P. R., Putatunda, R., Young, W.-B., Khalili, K., et al. (2015) · Scientific Reports · doi:10.1038/srep16277 · Cited by 160
Antiviral drug resistance in herpesviruses other than cytomegalovirus
Piret, J., & Boivin, G. (2014) · Reviews in Medical Virology · doi:10.1002/rmv.1787 · Cited by 159
Precise Gene Deletion and Replacement Using the CRISPR/Cas9 System in Human Cells
Zheng, Q., Cai, X., Tan, M. H., Schaffert, S. A., Arnold, C. P., Gong, X., Chen, C., & Huang, S. (2014) · BioTechniques · doi:10.2144/000114196 · Cited by 155
High-efficiency targeted editing of large viral genomes by RNA-guided nucleases
Bi, Y., Sun, L., Gao, D., Ding, C., Li, Z., Li, Y., Cun, W., & Li, Q. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004090 · Cited by 148
Sampaio, K. L., Cavignac, Y., Stierhof, Y., & Sinzger, C. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2754-2767.2005 · Cited by 141
van de Weijer, M. L., Bassik, M. C., Luteijn, R. D., Voorburg, C. M., Lohuis, M. A. M., Kremmer, E., Hoeben, R. C., LeProust, E. M., Chen, S., Hoelen, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms4832 · Cited by 127
Self-citationA DNA helicase induced by herpes simplex virus type 1
Crute, J. J., Mocarski, E. S., & Lehman, I. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.14.6585 · Cited by 118
Engineering large viral DNA genomes using the CRISPR‐Cas9 system
Suenaga, T., Kohyama, M., Hirayasu, K., & Arase, H. (2014) · Microbiology and Immunology · doi:10.1111/1348-0421.12180 · Cited by 95
Dynamic Epstein–Barr Virus Gene Expression on the Path to B-Cell Transformation
Price, A. M., & Luftig, M. A. (2014) · Advances in virus research · doi:10.1016/b978-0-12-800098-4.00006-4 · Cited by 93
Yin, Q., & Flemington, E. K. (2005) · Virology · doi:10.1016/j.virol.2005.11.021 · Cited by 88
State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.
Wang, D., & Gao, G. (2014) · PubMed · Cited by 87
State-of-the-art human gene therapy: part I. Gene delivery technologies.
Wang, D., & Gao, G. (2014) · PubMed · Cited by 87
Russell, T., Stefanovic, T., & Tscharke, D. C. (2014) · Journal of Virological Methods · doi:10.1016/j.jviromet.2014.11.009 · Cited by 86
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection
Wollebo, H. S., Bellizzi, A., Kaminski, R., Hu, W., White, M. K., & Khalili, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136046 · Cited by 78
Boissière, S. L., Izeta, A., Malcomber, S., & O’Hare, P. (2004) · Journal of Virology · doi:10.1128/jvi.78.15.8002-8014.2004 · Cited by 75
Characterization of naturally Epstein–Barr virus-infected gastric carcinoma cell line YCCEL1
Kim, D. N., Seo, M. K., Choi, H., Kim, S. Y., Shin, H. J., Yoon, A.-R., Tao, Q., Rha, S. Y., & Lee, S. K. (2012) · Journal of General Virology · doi:10.1099/vir.0.045237-0 · Cited by 69
Activities of ICP0 Involved in the Reversal of Silencing of Quiescent Herpes Simplex Virus 1
Ferenczy, M. W., Ranayhossaini, D., & DeLuca, N. A. (2011) · Journal of Virology · doi:10.1128/jvi.02265-10 · Cited by 52
Aubert, M., Boyle, N. M., Stone, D., Stensland, L., Huang, M.-L. W., Magaret, A., Galetto, R., Rawlings, D. J., Scharenberg, A. M., & Jerome, K. R. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.75 · Cited by 50
Nasimuzzaman, M., Kuroda, M., Dohno, S., Yamamoto, T., Iwatsuki, K., Matsuzaki, S., Rashel, M., Kumita, W., Mizuguchi, H., Hayakawa, T., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.017 · Cited by 41
Hill, G., Ku, E. S., & Dwarakanathan, S. (2014) · Disease-a-Month · doi:10.1016/j.disamonth.2014.03.003 · Cited by 40
Viral DNA Polymerase Inhibitors
Andreï, G., Clercq, E. D., & Snoeck, R. (2009) · Springer eBooks · doi:10.1007/b135974_22 · Cited by 32
Birlea, M., Nagel, M. A., Cohrs, R. J., Mahalingam, R., James, S. F., & Gilden, D. (2014) · Encyclopedia of the Neurological Sciences · doi:10.1016/b978-0-12-385157-4.00388-2 · Cited by 25
Flotte, T. R. (2013) · Molecular Therapy · doi:10.1038/mt.2013.226 · Cited by 24
UL84-independent replication of human cytomegalovirus strain TB40/E
Spector, D. J., & Yetming, K. D. (2010) · Virology · doi:10.1016/j.virol.2010.08.029 · Cited by 23
Gene transfer of integration defective anti-HSV-1 meganuclease to human corneas ex vivo
Elbadawy, H. M., Gailledrat, M., Desseaux, C., Salvalaio, G., Iorio, E. D., Ferrari, B., Bertolin, M., Barbaro, V., Parekh, M., Gayon, R., et al. (2014) · Gene Therapy · doi:10.1038/gt.2013.82 · Cited by 18
Cited by
SLC19A1 transports immunoreactive cyclic dinucleotides.
Luteijn, R. D., Zaver, S. A., Gowen, B. G., Wyman, S. K., Garelis, N. E., Onia, L., McWhirter, S. M., Katibah, G. E., Corn, J. E., Woodward, J. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1553-0 · Cited by 379
Nidhi, S., Anand, U., Oleksak, P., Tripathi, P., Lal, J. A., Thomas, G., Kuca, K., & Tripathi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073327 · Cited by 276
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
RETRACTED ARTICLE: Vasculogenic mimicry formation in EBV-associated epithelial malignancies
Xiang, T., Lin, Y.-X., Ma, W., Zhang, H.-J., Chen, K.-M., He, G.-P., Zhang, X., Xu, M., Feng, Q.-S., Chen, M.-Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07308-5 · Cited by 172
RetractedChiang, C., Pauli, E.-K., Biryukov, J., Feister, K. F., Meng, M., White, E. A., Münger, K., Howley, P. M., Meyers, C., & Gack, M. U. (2018) · Journal of Virology · doi:10.1128/jvi.01737-17 · Cited by 140
Metadata
- Authors
- van Diemen, F. R., Kruse, E. M., Hooykaas, M. J. G., Bruggeling, C. E., Schürch, A. C., van Ham, P. M., Imhof, S. M., Nijhuis, M., Wiertz, E. J. H. J., & Lebbink, R. J.
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-30
- Volume
- 12
- Issue
- 6
- Pages
- e1005701
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2464177244
- Cited by
- 290
- References
- 78
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.